TNFAIP3 gene rs7749323 polymorphism is associated with late onset myasthenia gravis

Abstract In this study, we intended to genotype 2 single nucleotide polymorphisms (SNPs) of tumor necrosis factor α-induced protein 3 (TNFAIP3) genes and explore an association of TNFAIP3 genetic polymorphism with the patients of myasthenia gravis (MG) at clinical level. In brief, 215 of adult MG patients were divided into subgroups according to their clinical features, age of onset, thymic pathology, and autoantibodies. Two hundred thirty-five of healthy controls were also divided into subgroups with gender- and age-matched. The allele and genotype frequencies of subgrouped patients were found to be higher than those of healthy controls. The distribution of TNFAIP3 gene rs7749323∗A allele of late onset MG (LOMG, with positive acetylcholine receptor antibody and without thymoma) subgrouped patients was also significantly higher than that of gender- and age-matched healthy controls (7.4% vs 2.4%, odds ratio [OR] = 3.27, 95% confidence interval [CI] 1.01–10.6, P = .04). Furthermore, analysis to the genotype frequencies indicates that the carriers of rs7749323∗A allele of LOMG group became more frequent than that of age-matched healthy controls (14.9% vs 4.8%, OR = 3.47, 95% CI 1.04–11.6, dominant model: P = .03). It is interesting to notice that there is no significant association between the rs7749323 and susceptibility of other MG subgroups. Therefore, it is suggested that the SNPs in the 3′ flanking region (rs7749323) of TNFAIP3 gene and the genetic variations of TNFAIP3 gene may take an important role in the susceptibility of LOMG.

[1]  Y. Li,et al.  GR gene polymorphism is associated with inter‐subject variability in response to glucocorticoids in patients with myasthenia gravis , 2016, European journal of neurology.

[2]  A. Marx,et al.  Genetic heterogeneity within the HLA region in three distinct clinical subgroups of myasthenia gravis. , 2016, Clinical immunology.

[3]  N. Gilhus,et al.  Myasthenia gravis — autoantibody characteristics and their implications for therapy , 2016, Nature Reviews Neurology.

[4]  Yaoxian Yue,et al.  Myasthenia gravis: subgroup classifications , 2016, The Lancet Neurology.

[5]  J. Mullikin,et al.  Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early onset autoinflammatory syndrome , 2015, Nature Genetics.

[6]  Annette Lee,et al.  Genome-Wide Association Study of Late-Onset Myasthenia Gravis: Confirmation of TNFRSF11A and Identification of ZBTB10 and Three Distinct HLA Associations , 2015, Molecular medicine.

[7]  Nils Erik Gilhus,et al.  Myasthenia gravis: subgroup classification and therapeutic strategies , 2015, The Lancet Neurology.

[8]  K. Rajesh,et al.  Ocular Myasthenia Gravis: A Review. , 2015 .

[9]  C. Quan,et al.  The TNFAIP3 polymorphism rs610604 both associates with the risk of psoriasis vulgaris and affects the clinical severity , 2015, Clinical and experimental dermatology.

[10]  Michael Benatar,et al.  A genome-wide association study of myasthenia gravis. , 2015, JAMA neurology.

[11]  A. Chan,et al.  Association of TNFAIP3 and TNFRSF1A variation with multiple sclerosis in a German case–control cohort , 2015, International journal of immunogenetics.

[12]  S. Ambika,et al.  The diagnostic yield of neuroimaging in sixth nerve palsy - Sankara Nethralaya Abducens Palsy Study (SNAPS): Report 1 , 2014, Indian journal of ophthalmology.

[13]  A. Marx,et al.  The Association of PTPN22 R620W Polymorphism Is Stronger with Late-Onset AChR-Myasthenia Gravis in Turkey , 2014, PloS one.

[14]  Liang Sun,et al.  CTLA4 Variants and Haplotype Contribute Genetic Susceptibility to Myasthenia Gravis in Northern Chinese Population , 2014, PloS one.

[15]  L. Catrysse,et al.  A20 in inflammation and autoimmunity. , 2014, Trends in immunology.

[16]  C. Ferran,et al.  Single nucleotide polymorphisms at the TNFAIP3/A20 locus and susceptibility/resistance to inflammatory and autoimmune diseases. , 2014, Advances in experimental medicine and biology.

[17]  Xinpeng Zhang,et al.  Single nucleotide polymorphisms in TNFAIP3 were associated with the risks of rheumatoid arthritis in northern Chinese Han population , 2014, BMC Medical Genetics.

[18]  Soumya Raychaudhuri,et al.  Risk for myasthenia gravis maps to a 151Pro→Ala change in TNIP1 and to human leukocyte antigen‐B*08 , 2012, Annals of neurology.

[19]  A. Ma,et al.  A20: linking a complex regulator of ubiquitylation to immunity and human disease , 2012, Nature Reviews Immunology.

[20]  Y. Lee,et al.  Associations between TNFAIP3 gene polymorphisms and systemic lupus erythematosus: a meta-analysis. , 2012, Genetic testing and molecular biomarkers.

[21]  S. Bae,et al.  Associations between TNFAIP3 gene polymorphisms and rheumatoid arthritis: a meta-analysis , 2012, Inflammation Research.

[22]  James T. Elder,et al.  TNFAIP3 Gene Polymorphisms Are Associated with Response to TNF Blockade in Psoriasis , 2011, The Journal of investigative dermatology.

[23]  Hai-feng Li,et al.  Association between HLA-DRB1 and myasthenia gravis in a northern Han Chinese population , 2011, Journal of Clinical Neuroscience.

[24]  G. van Loo,et al.  Genetic relationships between A20/TNFAIP3, chronic inflammation and autoimmune disease. , 2011, Biochemical Society transactions.

[25]  P. Kwok,et al.  Sequencing of TNFAIP3 and association of variants with multiple autoimmune diseases , 2011, Genes and Immunity.

[26]  D. Sanders,et al.  Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity , 2009, The Lancet Neurology.

[27]  Pui-Yan Kwok,et al.  Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus , 2008, Nature Genetics.

[28]  J. Aarli Myasthenia Gravis in the Elderly , 2008, Annals of the New York Academy of Sciences.

[29]  J. Sanders,et al.  A sensitive non-isotopic assay for acetylcholine receptor autoantibodies. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[30]  J. Oger Thymus Histology and Acetylcholine Receptor Antibodies in Generalized Myasthenia Gravis , 1993, Annals of the New York Academy of Sciences.

[31]  J. Oger,et al.  Acetylcholine Receptor Antibodies in Myasthenia Gravis: Use of a Qualitative Assay for Diagnostic Purposes , 1987, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.